The Effect of Sucralfate Slurry in Patients With Eosinophilic Esophagitis
NCT02353078 is a phase early 1 interventional trial sponsored by Mayo Clinic. As of 21 Nov 2026, it is completed. It studies Sucralfate in Eosinophilic Esophagitis. The registry lists an enrollment of 3 participants at 1 site in 1 country. The registry lists a start date of 31 Jan 2015 and a primary completion date of 31 Dec 2016.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT02353078 |
| Status | Completed |
| Phase | Phase Early 1 |
| Study type | Interventional trial |
| Lead sponsor | Mayo Clinic |
| Enrollment | 3 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Eosinophilic Esophagitis |
| Drugs | Sucralfate |
| Start | 31 Jan 2015 |
| Primary completion | 31 Dec 2016 |
| Study completion | 31 Dec 2016 |
| Last update posted | 11 Oct 2017 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- David Katzka, MD
Mayo Clinic
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Mayo Clinic in Rochester
Rochester
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT02353078
Each answer restates registry values shown on this page.
What is NCT02353078?
NCT02353078 is a phase early 1 interventional trial sponsored by Mayo Clinic. It studies Sucralfate in Eosinophilic Esophagitis.
Who leads NCT02353078?
The registry names David Katzka, MD (principal investigator, Mayo Clinic) as the overall official.
Where does NCT02353078 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT02353078 study?
The registered drug and biological interventions are Sucralfate.
When did NCT02353078 end?
The registry lists a primary completion date of 31 Dec 2016 and a study completion date of 31 Dec 2016. The sponsor last updated the record on 11 Oct 2017.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.